Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BioMarin Pharmaceutical (BMRN)

BioMarin closes $850 million senior notes offering to fund Amicus acquisition

Neutral Impact 4 of 5 financing Written later

BioMarin closed an $850 million private offering of 5.500% senior notes on February 12, 2026. The proceeds are held in escrow to help fund its pending acquisition of Amicus Therapeutics, alongside new term loans and a revolving credit facility.

Key points

  • $850 million of 5.500% senior unsecured notes due 2034 issued at 100.000% of face value
  • Proceeds held in escrow; notes must be redeemed at issue price plus accrued interest if the Amicus acquisition is not completed by December 19, 2026
  • Acquisition financing also includes a $2 billion term loan B, an $800 million term loan A and a $600 million revolving credit facility

The filing

CompanyBioMarin Pharmaceutical (BMRN)
Form8-K, current report
Filed with the SECFeb 12, 2026, 4:11 PM ET
Accession number0001193125-26-048736

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.